Growth hormone therapies like sermorelin have shown modest metabolic benefits in older adults, but evidence for enhanced weight loss when combined with GLP-1 drugs remains sparse
It produced an average weight loss of 22.7% in its Phase 3 REDEFINE 1 trial, the highest reported for any Novo Nordisk obesity drug to date
Putting the current evidence together The current evidence supports several clear conclusions: Menopause is associated with physiologic metabolic changes that contribute to weight gain and central adiposity
The translation of ATF4 mRNA increases through the general control non-derepressible-2 (GCN2)-eukaryotic initiation factor 2 (eIF2) signal axis
Lunch 32 g Chicken avocado wrap using 120 g cooked chicken, a small tortilla, lettuce, tomato, and a thin avocado spread
Typically, this fatigue passes within a few days as your system adjusts, eventually leading to more consistent energy levels